Skip to main content
    E

    Eton Pharmaceuticals Inc (ETON)

    Official site

    HEALTHCARE • DRUG MANUFACTURERS - SPECIALTY & GENERIC • NASDAQ

    $63.88
    -0.05 (-0.08%)

    Market Cap: $1.84B

    Last updated: Nov 17, 2026 at 11:05 AM ET

    Eton Pharmaceuticals Inc (ETON) Earnings: Report Dates and Results

    Updated Nov 5, 2026. Results come from company earnings reports, and estimates are consensus analyst estimates.

    Eton Pharmaceuticals (ETON) is expected to report earnings on Mar 17, 2027. In the quarter ended Sep 30, 2026, Eton Pharmaceuticals reported EPS of $1.06, above the $0.34 estimate. It beat the EPS estimate in 3 of the last 8 quarters.

    Earnings

    Performance (10Y)

    Beat Rate
    47%(14/30)
    Avg Surprise
    -35.51%
    Streak
    2 Q

    Upcoming Estimates

    Reports Mar 17, 2027 (est.)Period ending Dec 31, 2026
    EPS Consensus$0.43
    Range$0.29 - $0.58
    6 analysts
    Revenue Consensus
    $57.60M
    Range$46.55M - $63.24M
    6 analysts
    Reports May 12, 2027 (est.)Period ending Mar 31, 2027
    EPS Consensus$0.73
    Range$0.73 - $0.73
    1 analysts
    EPS Revisions
    0
    1
    30d
    EPS Estimate DriftChange to current
    90d ago$0.36+102.8%
    60d ago$0.47+55.3%
    30d ago$0.47+55.3%
    7d ago$0.45+62.2%
    Current$0.73
    Revenue Consensus
    $65.00M
    Range$63.50M - $66.50M
    2 analysts

    Next Report

    ETON has an expected report date of Mar 17, 2027. Analysts' consensus for the quarter ending Dec 31, 2026 is 126.3% above the $0.19 reported for the quarter ended Dec 31, 2025.

    ETON Earnings Call

    The latest ETON earnings call transcript on file is labeled 2026Q3.

    Read the 2026Q3 transcript

    Earnings History

    Of the 30 quarters below that had an estimate, ETON beat 14, missed 14 and matched 2. Revenue for the quarter ended Sep 30, 2026 was $57.92M, up 157.9% from $22.46M a year earlier.

    Quarter endedEPSEstimateRangeSurpriseResultYoYAnalystsRevisionsReportedRevenue
    Sep 30, 2026$1.06$0.34$0.32 - $0.42+211.76%Beat+2550.0%2N/ANov 5, 2026$57.92M
    Jun 30, 2026$0.35$0.11N/A+218.18%BeatN/A20 up, 1 downAug 13, 2026$37.59M
    Mar 31, 2026$0.14$0.14$0.14 - $0.140.00%In lineN/A10 up, 1 downMay 14, 2026$24.27M
    Dec 31, 2025$0.19$0.18N/A+5.56%BeatN/A11 up, 0 downMar 19, 2026$21.28M
    Sep 30, 2025$0.04$0.16$0.16 - $0.16-75.00%Miss+100.0%11 up, 0 downNov 6, 2025$22.46M
    Jun 30, 2025-$0.10-$0.01-$0.01 - $0.08-900.00%MissN/A31 up, 0 downAug 7, 2025$18.93M
    Mar 31, 2025-$0.06$0.05-$0.01 - $0.13-220.00%MissN/A31 up, 0 downMay 13, 2025$17.28M
    Dec 31, 2024-$0.02$0.00N/A-506.06%MissN/A20 up, 0 downMar 18, 2025$11.65M
    Sep 30, 2024$0.02-$0.01-$0.01 - -$0.01+300.00%BeatN/A20 up, 0 downNov 12, 2024$10.32M
    Jun 30, 2024-$0.12-$0.07-$0.07 - -$0.07-71.43%Miss-166.7%10 up, 0 downAug 8, 2024$9.07M
    Mar 31, 2024-$0.03-$0.07-$0.07 - -$0.07+57.14%BeatN/A10 up, 0 downMay 9, 2024$7.97M
    Dec 31, 2023-$0.09-$0.04-$0.04 - -$0.04-125.00%Miss-325.0%10 up, 0 downMar 14, 2024$7.31M
    Sep 30, 2023-$0.02-$0.10-$0.10 - -$0.10+80.00%BeatN/A10 up, 0 downNov 9, 2023$7.03M
    Jun 30, 2023$0.18-$0.09-$0.09 - -$0.09+300.00%BeatN/A10 up, 0 downAug 10, 2023$12.00M
    Mar 31, 2023-$0.10-$0.14-$0.14 - -$0.14+28.57%BeatN/A10 up, 0 downMay 11, 2023$5.30M
    Dec 31, 2022$0.04$0.01$0.01 - $0.01+300.00%Beat0.0%10 up, 0 downMar 16, 2023$8.50M
    Sep 30, 2022-$0.12-$0.15-$0.15 - -$0.15+20.00%BeatN/A10 up, 0 downNov 10, 2022$3.22M
    Jun 30, 2022-$0.06$0.03$0.03 - $0.03-300.00%MissN/A10 up, 1 downAug 11, 2022$7.36M
    Mar 31, 2022-$0.21-$0.08-$0.19 - $0.03-162.50%Miss-210.5%20 up, 0 downMay 12, 2022$2.18M
    Dec 31, 2021$0.04$0.19N/A-78.95%MissN/AN/A0 up, 0 downMar 16, 2022$6.09M
    Sep 30, 2021-$0.24-$0.13N/A-84.62%MissN/A11 up, 0 downNov 15, 2021$775000
    Jun 30, 2021-$0.10-$0.14-$0.20 - -$0.08+28.57%BeatN/A2N/AAug 16, 2021$3.07M
    Mar 31, 2021$0.19$0.19$0.19 - $0.190.00%In lineN/A2N/AMay 13, 2021$11.90M
    Dec 31, 2020-$0.32-$0.26-$0.26 - -$0.26-23.08%MissN/A2N/AMar 16, 2021$180000
    Sep 30, 2020-$0.31-$0.25-$0.32 - -$0.20-24.00%MissN/A3N/ANov 12, 2020N/A
    Jun 30, 2020-$0.23-$0.26-$0.29 - -$0.22+11.54%BeatN/A3N/AAug 12, 2020$20000
    Mar 31, 2020-$0.50-$0.23-$0.33 - -$0.14-117.39%MissN/A3N/AMay 14, 2020N/A
    Dec 31, 2019-$0.15-$0.26-$0.34 - -$0.21+42.31%BeatN/A3N/AMar 5, 2020$459000
    Sep 30, 2019-$0.28-$0.24-$0.28 - -$0.22-16.67%MissN/A3N/ANov 14, 2019N/A
    Jun 30, 2019-$0.18-$0.28N/A+35.71%BeatN/A1N/AAug 6, 2019N/A
    Mar 31, 2019-$0.42N/AN/AN/AN/AN/AN/AN/AMay 7, 2019$500000
    Dec 31, 2018-$1.48N/AN/AN/AN/AN/AN/AN/AMar 25, 2019N/A
    Sep 30, 2018-$0.53N/AN/AN/AN/AN/AN/AN/ADec 20, 2018N/A
    Jun 30, 2018-$0.23N/AN/AN/AN/AN/AN/AN/AAug 10, 2018N/A
    Last 34 quarters

    Annual EPS

    EPS for the fiscal year ended Dec 31, 2025 was $0.07, a profit after a loss of $0.15 per share the year before. It was -$2.24 for the year ended Dec 31, 2018, the oldest of the 8 fiscal years shown.

    Fiscal year endedEPSChange
    Dec 31, 2025$0.07N/A
    Dec 31, 2024-$0.15N/A
    Dec 31, 2023-$0.03N/A
    Dec 31, 2022-$0.35N/A
    Dec 31, 2021-$0.11N/A
    Dec 31, 2020-$1.36N/A
    Dec 31, 2019-$1.03N/A
    Dec 31, 2018-$2.24N/A

    Earnings Calls

    The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 5,600 words across 9 speakers.

    CallPeriod endingWordsSpeakersTranscript
    2026Q3Sep 30, 20265,6199
    2026Q2Jun 30, 20265,9309
    2026Q1Mar 31, 20265,4298
    2025Q4Dec 31, 20257,5058
    2025Q3Sep 30, 20254,7697
    2025Q2Jun 30, 20255,0067
    2025Q1Mar 31, 20255,4787
    2024Q4Dec 31, 20243,8897

    2026Q3 Earnings Call

    Opening remarks

    David Krempa Chief Business Officer Thank you, operator. Good afternoon, everyone, and welcome to Eton's Third Quarter 2026 Conference Call. This afternoon, we issued our earnings release, which is available on our website, etonpharma.com. Joining me today are Sean Brynjelsen, our CEO; Ipek Trinkaus, our Chief Commercial Officer; and Judy Matthews, our Chief Financial Officer. Before we begin, I would like to remind everyone that remarks made during the call may contain forward-looking statements and involve risks and uncertainties that could cause actual results to differ materially from those contained in these forward-looking statements. Please see the forward-looking statements disclaimer in our earnings release and the risk factors in the company's filings with the SEC. Now I will turn the call over to our CEO, Sean Brynjelsen.

    Sean Brynjelsen CEO Thank you, David. Good afternoon, everyone, and thank you for joining us today. It was another outstanding quarter for Eton with record revenue, significant margin expansion and strong cash flow generation. We continue to fire on all cylinders on both the commercial and development fronts. Revenue grew a remarkable 158% year-over-year, reaching $57.9 million in the quarter. The third quarter was the first with a full quarter of HEMANGEOL revenue, which was a significant growth driver, but we also saw strength across all our key products. In fact, we hit record-high levels of active patient counts in the quarter on all of our key branded products, including INCRELEX, HEMANGEOL, ALKINDI SPRINKLE, KHINDIVI, GALZIN and DESMODA. At the start of 2026, we set three ambitious long-term goals for the company to help articulate to investors where we saw our business heading in the coming years. We like to set aspirational goals that push the envelope, not easy goals, and I know there was initially some skepticism about how achievable our goals were. From today's results, it's clear we are well ahead of that schedule. Our first goal was to reach a $200 million annualized revenue run rate by the end of 2027. We exited 2025 at about an $85 million run rate. So this required us to more than double our revenue within 24 months. As you saw, with nearly $58 million of revenue this quarter, we far exceeded this goal and did so an impressive five quarters ahead of schedule. Our second goal was focused on profitability, to produce a 50% adjusted EBITDA margin by 2028, up from the 20% we reported in 2025. It happened much faster. This quarter, we achieved a 49% adjusted EBITDA margin even after the expensing of our $3 million licensing payment for ASN-001, which was not adjusted out of the calculation.

    Frequently Asked Questions About ETON

    When is Eton Pharmaceuticals's next earnings date?

    Eton Pharmaceuticals's next earnings report is expected for Mar 17, 2027.

    Did ETON beat earnings estimates last quarter?

    Yes. Eton Pharmaceuticals reported EPS of $1.06 for the quarter ended Sep 30, 2026, above the $0.34 estimate, a 211.76% surprise.

    What EPS do analysts expect from ETON next quarter?

    The consensus EPS estimate for Eton Pharmaceuticals for the quarter ending Dec 31, 2026 is $0.43 from 6 analysts, with estimates from $0.29 to $0.58.

    How often does ETON beat earnings estimates?

    Eton Pharmaceuticals beat the EPS estimate in 3 of the last 8 quarters, with an average surprise of -158.19%.